9 results on '"Response to treatment"'
Number of results to display per page
Search Results
2. Monitoring der Progression von geografischer Atrophie in der optischen Kohärenztomographie.
- Author
-
Schmidt-Erfurth, Ursula, Mai, Julia, Reiter, Gregor S., Riedl, Sophie, Lachinov, Dmitrii, Vogl, Wolf-Dieter, and Bogunovic, Hrvoje
- Abstract
Copyright of Die Ophthalmologie is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2023
- Full Text
- View/download PDF
3. Methoden zur Erfassung der Krankheitsaktivität der Polymyalgia rheumatica.
- Author
-
Reisch, Myriam and Dejaco, Christian
- Abstract
Copyright of Zeitschrift für Rheumatologie is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2023
- Full Text
- View/download PDF
4. [Head-to-head studies on radiographic progression in axial spondyloarthritis].
- Author
-
Kiltz U and Haibel H
- Subjects
- Humans, Adalimumab therapeutic use, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Drug Therapy, Combination, Evidence-Based Medicine, Radiography, Treatment Outcome, Antirheumatic Agents therapeutic use, Axial Spondyloarthritis drug therapy, Axial Spondyloarthritis diagnostic imaging, Disease Progression
- Abstract
In this review article four clinical comparative studies in axial spondylarthritis (axSpA) are presented and discussed. SURPASS as the only head-to-head study investigated the effect of adalimumab biosimilar disease-modifying antirheumatic drug (bsDMARD) or secukinumab on radiographic progression over a time period of 2 years. Overall, the radiographic progression of the spine was low and no significant difference between adalimumab bsDMARD or secukinumab was noted. The three other studies were not constructed as direct head-to-head studies but compared the efficacy of non-steroidal antirheumatic drugs (NSARD) with and without simultaneous treatment with biological DMARDs (bDMARD). The CONSUL study showed no statistically significant difference in the delay of radiographic progression of the spine over 2 years in radiographic axSpA (r-axSpA) patients, who underwent either combined treatment with golimumab and celecoxib or treatment with golimumab alone over 2 years. The ESTHER study showed that patients with early axSpA active inflammatory lesions, which were detected by whole-body magnetic resonance imaging (MRI), showed a significantly greater improvement under treatment with etanercept than those treated with sulfasalazine. The INFAST study showed that patients with early active axSpA who received a combined treatment of infliximab and naproxen, achieved a clinical remission twice as frequently as those who only received naproxen. Therefore, for the endpoint of radiological progression no difference could be shown in the inhibition of radiological progression between the mechanisms of action investigated. The comparative data for the endpoint of clinical efficacy showed that patients with bDMARDs showed a clearly better response to treatment than patients with NSAR or conventional synthetic DMARDs (csDMARD)., (© 2024. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
5. [Monitoring of the progression of geographic atrophy with optical coherence tomography].
- Author
-
Schmidt-Erfurth U, Mai J, Reiter GS, Riedl S, Lachinov D, Vogl WD, and Bogunovic H
- Subjects
- Humans, Tomography, Optical Coherence methods, Artificial Intelligence, Fluorescein Angiography methods, Retinal Pigment Epithelium, Disease Progression, Geographic Atrophy diagnosis
- Abstract
With the prospect of available therapy for geographic atrophy in the near future and consequently increasing patient numbers, appropriate management strategies for the clinical practice are needed. Optical coherence tomography (OCT) as well as automated OCT analysis using artificial intelligence algorithms provide optimal conditions for assessing disease activity as well as the treatment response for geographic atrophy through a rapid, precise and resource-efficient evaluation., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
6. [Methods for assessment of disease activity of polymyalgia rheumatica].
- Author
-
Reisch M and Dejaco C
- Subjects
- Humans, Biomarkers, Blood Sedimentation, C-Reactive Protein analysis, Polymyalgia Rheumatica diagnosis, Polymyalgia Rheumatica drug therapy, Giant Cell Arteritis
- Abstract
Polymyalgia rheumatica (PMR) is the second most frequent inflammatory rheumatic disease in old age. Remission and recurrence are frequently used as endpoints in clinical trials; however, there is as yet no international consensus on the definition of these states, which limits the comparability of published studies. The PMR activity score (PMR-AS) is the only composite score specifically developed for PMR, which together with remission is used to define low, middle and high disease activity. In recent studies the PMR-AS was often used and low disease activity was established as endpoint. The most important limitation of the PMR-AS is the potential influence of the individual variables by comorbidities. The value of C‑reactive protein (CRP) and the erythrocyte sedimentation rate (ESR) are of restricted value in studies using drugs that influence the interleukin 6 (IL-6) axis. In these cases, calprotectin and osteopontin are promising alternative biomarkers, as they have already been shown to reflect disease activity independently of CRP in rheumatoid arthritis. Furthermore, imaging modalities including sonography, magnetic resonance imaging and fluorodeoxyglucose (FDG) positron emission tomography could also be helpful in monitoring disease activity; however, these techniques must first be validated in further studies. The PMR impact scale (PMR-IS) is a composite score to assess the impact of PMR on the patients; however, it has not yet been used in clinical studies. The development of additional patient reported outcomes (PRO) for PMR and the definition of standardized criteria for documentation of remission and recurrence are important questions in the future research agenda for PMR., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
7. [Clinical characteristics of Idiopathic Epilepsy in Greater Swiss Mountain Dogs in Switzerland]
- Author
-
S Sauer-Delhées, Katrin Beckmann, Iris M Reichler, and Frank Steffen
- Subjects
Pediatrics ,medicine.medical_specialty ,Greater Swiss Mountain Dog ,Population ,biology.animal_breed ,Status epilepticus ,Breeding ,Disease cluster ,Epilepsy ,Dogs ,Surveys and Questionnaires ,Seizure control ,medicine ,Prevalence ,Animals ,Dog Diseases ,education ,education.field_of_study ,General Veterinary ,biology ,business.industry ,medicine.disease ,Response to treatment ,Breed ,medicine.symptom ,business ,Switzerland - Abstract
Background: Little is known about idiopathic Epilepsy in Greater Swiss Mountain Dogs. Until now this breed is not listed as a predisposed breed for idiopathic epilepsy. The aim of this study was to estimate the prevalence of idiopathic epilepsy in Greater Swiss Mountain Dogs in Switzerland and to describe the clinical characteristics of epilepsy in this breed including seizures semiology and response to treatment. Material and Methods: Records of the Swiss Kennel Club for Greater Swiss Mountain Dogs were searched for reported cases of epileptic seizures between 1999-2019. The total number of reported cases and the signalment was reviewed. Furthermore, all owners of Greater Swiss Mountain Dogs registered to the breeding club were invited to complete an online questionnaire. Results: In total 600 Greater Swiss Mountain Dog's live in Switzerland: 70-90 puppies are born each year. Between 1999 and 2019 34 dogs (2%) were announced with seizures. Of the 400 owners invited to answer the questionnaire 128 completed the questionnaire. 20 of these 128 dogs were suffering from idiopathic epilepsy. The prevalence for idiopathic epilepsy based on the questionnaire was therefore 15,6%. All affected dogs showed generalized tonic-clonic seizures. Cluster seizures and status epilepticus occurred in 5 (41,6%) and 6 (50%) of the dogs. Long term seizure control was only achieved in 10% of the dogs. Five dogs (25%) died or were euthanized because of insufficient seizure control. Only one dog (5%) showed clinical remission. Conclusion: Prevalence of idiopathic epilepsy is higher in Greater Swiss Mountain Dogs in Switzerland compared to the general dog population. Seizure control seems to be difficult to achieve in this breed and remission-rate is low.Hintergrund: Bisher wird der Grosse Schweizer Sennenhund nicht unter den prädisponierten Rassen für idiopathische Epilepsie geführt. Allerdings liegen hierzu bisher auch nur wenige Daten und keine wissenschaftlichen Studien vor. Ziel dieser Studie ist es, die Häufigkeit der idiopathischen Epilepsie bei Grossen Schweizer Sennenhunden zu erheben und Anfallscharakteristik, Therapieprotokolle und -erfolge bei den betroffenen Hunden zu dokumentieren, um das Risiko für diese Erkrankung und den Verlauf besser einschätzen zu können. Material und Methoden: Es wurden Unterlagen des Schweizer Zuchtverbandes «Klub für Grosse Schweizer Sennenhunde» mit gemeldeten Fällen von epileptischen Anfällen ab Geburtsjahr 1999–2019 analysiert. Zusätzlich wurde eine Einladung zu einer Online-Umfrage zur idiopathischen Epilepsie (Einteilung Anfälle ja/nein, wenn ja; Angaben zu Anfallscharakteristik, Therapie, Therapieerfolge) an die Mitglieder des Zuchtverbandes verschickt. Ergebnisse: In der Schweiz besteht die Population aus ca. 600 Tieren, 70–90 Welpen werden pro Jahr geboren. Im Zeitraum zwischen 1999 und 2019 wurden dem Zuchtverband 34 Hunde mit Epilepsie in der Schweiz gemeldet, das entspricht einer Rate von an Epilepsie erkrankten Hunden von ca. 2%. 400 Tierbesitzer wurden zur Umfrage eingeladen und 128 nahmen teil. Die Prävalenz von idiopathischer Epilepsie beim Grossen Schweizer Sennenhund betrug mit 20 erkrankten Hunden 15,6%. Alle betroffenen Tiere zeigten generalisierte tonisch-klonische Anfälle. Bei 5 Tieren (41,6%) trat ein Status epilepticus auf. Bei 6/12 (50%) Hunden traten Clusteranfälle auf. Andauernde Therapieerfolge wurden nur bei 10% erzielt, 25% sind verstorben und Remission wurde ausschliesslich bei einem Hund (5%) erreicht. Schlussfolgerungen: Die Prävalenz der idiopathischen Epilepsie in Grossen Schweizer Sennenhunden in der Schweiz ist höher als in der durchschnittlichen Hundepopulation (0,6–0,75%). Status epilepticus und Clusteranfälle sind häufig, eine Remission ist sehr selten.Contexte: On sait peu de choses sur l’épilepsie idiopathique chez les Grands Bouviers Suisses. Jusqu’à présent, cette race n’est pas répertoriée comme une race prédisposée à l’épilepsie idiopathique. Le but de cette étude était d’estimer la prévalence de l’épilepsie idiopathique chez les Grands Bouviers Suisses en Suisse et de décrire les caractéristiques cliniques de l’épilepsie chez cette race, y compris la sémiologie des crises et la réponse au traitement. Matériel et méthodes: Les archives de l’association d’élevage «Club des Grands Bouviers Suisses» ont été étudiées pour les cas signalés de crises d’épilepsie entre 1999 et 2019. Le nombre total de cas signalés et le signalement ont été examinés. De plus, tous les propriétaires de Grands Bouviers Suisses inscrits au club d’élevage ont été invités à remplir un questionnaire en ligne. Résultats: Au total 600 Grands Bouviers Suisses vivent en Suisse et 70 à 90 chiots naissent chaque année. Entre 1999 et 2019, 34 chiens (2%) ont fait l’objet de crises d’épilepsie. Sur les 400 propriétaires invités à répondre au questionnaire, 128 ont rempli le questionnaire. 20 de ces 128 chiens souffraient d’épilepsie idiopathique. La prévalence de l’épilepsie idiopathique sur la base du questionnaire était donc de 15,6%. Tous les chiens atteints ont présenté des crises tonico-cloniques généralisées. Chez 5 animaux (41,6%) un status epilepticus est survenu et des crises en série chez 6 animaux (50%). Le contrôle à long terme des crises n’a été obtenu que chez 10% des chiens. Cinq chiens (25%) sont morts ou ont été euthanasiés en raison d’un contrôle insuffisant des crises. Un seul chien (5%) a présenté une rémission clinique. Conclusion: La prévalence de l’épilepsie idiopathique est plus élevée chez les Grands Bouviers Suisses en Suisse que dans la population canine générale. Le contrôle des crises semble difficile à réaliser dans cette race et le taux de rémission est faible.Stato dell’arte: L’epilessia idiopatica del grande bovaro svizzero è stata finora poco investigata. Attualmente questa razza non è inclusa nelle razze predisposte all’epilessia idiopatica. Lo scopo di questo studio è di investigare la prevalenza dell’epilessia idiopatica nel grande bovaro svizzero in una popolazione svizzera e descrivere le caratteristiche cliniche di questa patologia in questa razza canina includendo la semeiotica delle crisi epilettiche e la risposta clinica alla terapia. Materiali e metodi: le storie cliniche dei grandi bovari svizzeri iscritti al club cinofilo svizzero sono state ricercate in un intervallo temporale compreso tra il 1999–2019 al fine di segnalare casi affetti da epilessia idiopatica. Sono stati esaminati il numero totale dei casi e il relativo segnalamento. Inoltre, tutti i proprietari del grande bovaro svizzero registrati in allevamenti ufficiali sono stati invitati a compilare un questionario online. Risultati: in totale in Svizzera sono registrati 600 soggetti di grande bovaro svizzero: ogni anno nascono tra i 70 ed i 90 cuccioli. Tra il 1999 e il 2019 sono stati segnalati 34 soggetti (2%) affetti da crisi epilettiche. Il questionario online è stato compilato da 128 su 400 proprietari contattati. Venti proprietari su 128 hanno segnalato la presenza di crisi epilettiche di natura idiopatica. La relativa prevalenza dell’epilessia idiopatica riscontrata è risultata, dunque, pari al 15,6% basandosi sui dati derivati dal questionario. Tutti i soggetti affetti presentavano crisi epilettiche di tipo tonico-clonico. Cinque soggetti (41,6%) sono stati affetti da status epilepticus. Sei soggetti su dodici (50%) hanno presentato crisi di tipo cluster. Il controllo a lungo termine delle crisi è stato possibile solo nel 10% dei casi. Cinque soggetti (25%) sono deceduti, un solo soggetto (5%) ha presentato remissioni dei sintomi clinici. Conclusioni: la prevalenza dell’epilessia idiopatica nel grande bovaro svizzero in Svizzera è più grande se confrontata con quella generale nella popolazione canina. Lo stato epilettico e le crisi di tipo cluster sono comuni in questa razza, mentre la percentuale di soggetti che recuperano dai sintomi clinici è bassa.
- Published
- 2020
8. Ultrasound in the assessment of tumor response in the age of targeted and immuno-oncology therapies back to the future
- Author
-
Fabio Piscaglia, Boris Brkljačić, Francesco Tovoli, Vito Cantisani, Tovoli F., Piscaglia F., Brkljacic B., and Cantisani V.
- Subjects
Oncology ,Oncolytic Virotherapy ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,ultrasound ,malignant tumors ,response to treatment ,Ultrasound ,MEDLINE ,Immunotherapy ,Tumor response ,Oncolytic virus ,Text mining ,Neoplasms diagnosis ,Internal medicine ,Neoplasms ,Humans ,immunotherapy ,oncolytic virotherapy ,ultrasonography ,neoplasms ,medicine ,Radiology, Nuclear Medicine and imaging ,Ultrasonography ,business ,Human - Abstract
The editorial is presenting the role of modern ultrasound techniques in the assessment of the efficacy of treatment of various malignant tumors
- Published
- 2019
9. Cutaneous leishmaniasis: clinical report of two cases and review of the recent literature
- Author
-
Roland Kaufmann, Eva Maria Valesky, Markus Meissner, Manfred Wolter, Helmut Schöfer, Diamant Thaçi, and Christian Beier
- Subjects
Adult ,Pregnancy ,medicine.medical_specialty ,business.industry ,Leishmaniasis, Cutaneous ,Dermatology ,Mucosal disease ,Controlled studies ,medicine.disease ,Response to treatment ,Anti-Bacterial Agents ,Clinical report ,Treatment Outcome ,Cutaneous leishmaniasis ,Treatment modality ,Cryotherapy ,Child, Preschool ,Medicine ,Humans ,Female ,business - Abstract
Summary With 1–1.5 million cases reported every year cutaneous leishmaniasis represents an increasing health problem. The course of cutaneous leishmaniasis varies from a single self-healing ulcer to a persistent ulcer or progressive mucosal disease with nasopharyngeal destruction. An enormous array of topical and systemic treatment modalities has been endorsed. The response to treatment depends on the species of parasite as well as the host's immunological and genetic status. Species-specific treatment guidelines based on evidence from controlled studies are highly desirable. We present two cases of cutaneous leishmaniasis, one in a child and one during pregnancy, reviewing various diagnostic and therapeutic measures with special attention to problems in young and pregnant patients.
- Published
- 2007
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.